Sabine Huenecke
Overview
Explore the profile of Sabine Huenecke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy
Gierschek F, Schlueter J, Kuhnel I, Feigl F, Schmiedel D, Prufer M, et al.
Transfus Med Hemother
. 2025 Feb;
52(1):42-60.
PMID: 39944413
Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a high relapse rate and still limited therapeutic options. Natural killer (NK) cell-based immunotherapy has the potential to improve...
2.
Fekadu-Siebald J, Fuchs N, Zahn S, Rommel M, Schenk F, Huenecke S, et al.
Stem Cell Res
. 2024 Nov;
81:103598.
PMID: 39522300
Leukocyte Adhesion Deficiency Type I (LAD I) is a rare inborn error of immunity caused by mutations in the ITGB2 gene coding for β2-integrin CD18 on the surface of leukocytes....
3.
Bonig H, Verbeek M, Herhaus P, Braitsch K, Beutel G, Schmid C, et al.
J Transl Med
. 2024 Jun;
22(1):566.
PMID: 38872104
No abstract available.
4.
Enssle J, Campe J, Moter A, Voit I, Gessner A, Yu W, et al.
Leukemia
. 2023 Dec;
38(1):168-180.
PMID: 38049509
Patients with multiple myeloma (MM) routinely receive mRNA-based vaccines to reduce COVID-19-related mortality. However, whether disease- and therapy-related alterations in immune cells and cytokine-responsiveness contribute to the observed heterogeneous vaccination...
5.
Bonig H, Verbeek M, Herhaus P, Braitsch K, Beutel G, Schmid C, et al.
J Transl Med
. 2023 Nov;
21(1):837.
PMID: 37990219
Background: Patients with steroid-refractory acute graft-versus-host disease (aGvHD) not tolerating/responding to ruxolitinib (RR-aGvHD) have a dismal prognosis. Methods: We retrospectively assessed real-world outcomes of RR-aGvHD treated with the random-donor allogeneic...
6.
Piede N, Bremm M, Farken A, Pfeffermann L, Cappel C, Bonig H, et al.
Cells
. 2023 Mar;
12(6).
PMID: 36980191
Mesenchymal stromal cells (MSCs) have the potential to suppress pathological activation of immune cells and have therefore been considered for the treatment of Graft-versus-Host-Disease. The clinical application of MSCs requires...
7.
Bakhtiar S, Kaffenberger C, Salzmann-Manrique E, Donhauser S, Lueck L, Karaca N, et al.
J Autoimmun
. 2022 Sep;
132:102891.
PMID: 36113303
Background: Immune dysregulation as a result of an inborn error of immunity (IEI) leads to the complicated symptoms of refractory multi-organ immune dysregulation. B lymphocytes with immune regulatory capacity (Breg)...
8.
Enssle J, Campe J, Buchel S, Moter A, See F, Griessbaum K, et al.
Cancer Cell
. 2022 May;
40(6):587-589.
PMID: 35588736
No abstract available.
9.
Jarisch A, Wiercinska E, Huenecke S, Bremm M, Cappel C, Hauler J, et al.
Transplant Cell Ther
. 2022 Apr;
28(7):366.e1-366.e7.
PMID: 35472554
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are capable of inducing combined humoral and cellular immunity. Which effect is more relevant for their potent protective effects is unclear, but...
10.
Peinelt A, Bremm M, Kreyenberg H, Cappel C, Banisharif-Dehkordi J, Erben S, et al.
Front Immunol
. 2022 Mar;
13:830773.
PMID: 35309367
Chimeric antigen receptor (CAR) T cell therapy is a potent new treatment option for relapsed or refractory hematologic malignancies. As the monitoring of CAR T cell kinetics can provide insights...